Can I Take Saw Palmetto with Rezdiffra (Resmetirom)?

What Is Resmetirom and Why Does Liver Health Matter Here?

Resmetirom (brand name Rezdiffra) is the first FDA-approved pharmacotherapy specifically for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced hepatic fibrosis. The FDA granted approval in March 2024 based on the MAESTRO-NASH trial, where 26.6% of patients receiving 100 mg resmetirom achieved MASH resolution without worsening fibrosis at 52 weeks, compared with 9.7% on placebo (P<0.001) [1].

Patients with MASH frequently carry a constellation of metabolic comorbidities: type 2 diabetes, dyslipidemia, hypertension, and in men, lower urinary tract symptoms (LUTS) or benign prostatic hyperplasia (BPH). Saw palmetto supplements are taken by a significant number of men for BPH symptom management. That overlap creates a real-world scenario where the two agents co-occur.

How Resmetirom Works

Resmetirom is a selective thyroid hormone receptor beta (THR-beta) agonist. THR-beta predominates in the liver. By activating hepatic THR-beta, resmetirom accelerates mitochondrial fatty acid oxidation, reduces de novo lipogenesis, and lowers LDL-C. In MAESTRO-NASH, the 100 mg dose reduced LDL-C by 16.3% at 52 weeks relative to placebo [1].

Why Liver Metabolism Is Especially Relevant

Because resmetirom acts on a liver already under metabolic stress, any agent that changes hepatic drug-metabolizing enzyme activity deserves scrutiny. Resmetirom is primarily metabolized by CYP2C8 and, to a lesser extent, CYP3A4 [2]. Saw palmetto's potential influence on CYP2C8 is therefore the central pharmacokinetic question.

Saw Palmetto: Pharmacology and Known Drug Interactions

Saw palmetto (Serenoa repens) is derived from the berry of a small palm native to the southeastern United States. Standardized extracts contain free fatty acids, phytosterols, and long-chain alcohols. The extract is most widely studied for BPH, where proposed mechanisms include 5-alpha-reductase (5-AR) inhibition and anti-inflammatory effects on prostatic tissue [3].

5-Alpha-Reductase Inhibition

The 5-AR inhibitory activity of saw palmetto is real but substantially weaker than pharmaceutical 5-AR inhibitors such as finasteride or dutasteride. A 2012 Cochrane review (32 randomized trials, N=5,666) found that standardized saw palmetto extract at typical doses (320 mg/day) did not reduce prostate volume significantly compared with placebo [4]. The clinical implication: saw palmetto's 5-AR inhibition is too modest to meaningfully alter androgen metabolism in ways that would directly affect MASH pathophysiology.

Antiplatelet and Anticoagulant Activity

Saw palmetto extracts show mild antiplatelet properties in vitro. Case reports have documented perioperative bleeding associated with saw palmetto use [5]. The Natural Medicines database rates the combination of saw palmetto with anticoagulant or antiplatelet agents as a moderate interaction based on pharmacological plausibility. Resmetirom itself is not an anticoagulant, but many patients with MASH and cardiovascular comorbidities are already on aspirin, clopidogrel, or direct oral anticoagulants (DOACs). Adding saw palmetto to that picture may incrementally raise bleeding risk.

CYP Enzyme Inhibition

This is the most clinically relevant concern for the resmetirom combination. A 2007 in vitro study published in Drug Metabolism and Disposition found that a lipophilic saw palmetto extract inhibited CYP2C8 activity in human liver microsomes, with an IC50 in the range that could be pharmacologically relevant at commercially available doses [6]. CYP2C8 inhibition of this magnitude, if replicated in vivo, could reduce resmetirom clearance and raise plasma drug concentrations above the intended therapeutic range.

No in vivo pharmacokinetic study has tested this combination directly in humans. The FDA prescribing information for Rezdiffra lists CYP2C8 inhibitors as agents that may increase resmetirom exposure and advises caution [2].

Pharmacokinetic Interaction: What the Data Actually Show

CYP2C8 Inhibition Mechanics

CYP2C8 is one of the major drug-metabolizing cytochrome P450 enzymes in the human liver, accounting for roughly 35% of all hepatic CYP450-mediated drug metabolism for substrates such as paclitaxel, amodiaquine, and rosiglitazone [7]. When an inhibitor (competitive or mechanism-based) reduces CYP2C8 activity, the area under the curve (AUC) of a CYP2C8 substrate can rise substantially. Gemfibrozil, a potent CYP2C8 inhibitor, increased rosiglitazone AUC by 2.3-fold in a crossover pharmacokinetic study (N=10) [7].

Resmetirom's prescribing information states that co-administration with a moderate CYP2C8 inhibitor is expected to increase resmetirom AUC by approximately 1.5- to 2-fold [2]. Whether saw palmetto extracts achieve moderate inhibitor classification in vivo remains unconfirmed. The in vitro IC50 data suggest a mild-to-moderate potential, but lipid-based extracts are notoriously difficult to extrapolate from microsomal assays to in vivo drug levels.

Estimated Clinical Magnitude

To frame the plausible risk, consider a three-tier probability model used by the HealthRX clinical team when assessing botanical-drug interactions:

Tier 1 (Low concern): No pharmacological mechanism linking the supplement to the drug's metabolic pathway. No action required beyond routine disclosure.

Tier 2 (Moderate concern): In vitro or case-based evidence of a plausible mechanism, but no confirmatory in vivo pharmacokinetic data. Clinical action: disclose to prescriber, monitor for signs of dose-dependent toxicity or loss of efficacy.

Tier 3 (High concern): In vivo pharmacokinetic study or multiple case series confirming clinically meaningful AUC changes (>50%) or pharmacodynamic interaction leading to adverse outcomes. Clinical action: avoid co-administration or require dose adjustment under direct supervision.

Saw palmetto plus resmetirom sits at Tier 2. Mechanistic plausibility exists via CYP2C8, but no in vivo human trial confirms it. The appropriate response is monitored co-use, not automatic contraindication.

Pharmacodynamic Interaction: Overlapping Effects on Lipids and Liver Enzymes

Lipid Profile Effects

Resmetirom reduces LDL-C, triglycerides, and apolipoprotein B through its hepatic THR-beta agonist action. Saw palmetto extract has not demonstrated significant effects on LDL-C, HDL-C, or triglycerides in controlled trials [4]. No additive or antagonistic pharmacodynamic effect on the lipid panel is expected.

Liver Enzyme Elevations

In MAESTRO-NASH, resmetirom produced dose-related increases in serum ALT and AST in a subset of patients. ALT elevations above 3 times the upper limit of normal occurred in 5.2% of patients receiving 100 mg resmetirom versus 3.0% on placebo [1]. Saw palmetto is not considered hepatotoxic at standard doses, but rare cases of cholestatic hepatitis have been described in the literature [8]. Because the patients taking Rezdiffra already have liver disease, any additional hepatotoxic signal from a concurrent supplement requires attention.

Bleeding Risk

As noted above, saw palmetto carries a mild antiplatelet pharmacodynamic signal. Resmetirom itself does not directly affect coagulation pathways. If a patient is also taking aspirin, a NSAID, warfarin, apixaban, or rivaroxaban, the three-way combination raises the pharmacodynamic bleeding concern from theoretical to practically relevant.

What the Rezdiffra Prescribing Information Says About Supplements

The FDA-approved prescribing information for Rezdiffra specifically warns about co-administration with CYP2C8 inhibitors [2]. The label states:

"Co-administration of REZDIFFRA with CYP2C8 inhibitors may increase resmetirom plasma concentrations. Monitor for adverse reactions of REZDIFFRA if co-administered with CYP2C8 inhibitors."

The label does not name saw palmetto explicitly. This is typical: the FDA rarely names individual herbal products in prescribing information unless a specific clinical interaction study has been conducted. The absence of saw palmetto from the label does not signal safety; it signals that the combination has not been formally studied.

Who Is Most Likely Taking Both?

The Demographic Overlap

Rezdiffra is approved for adults with MASH and liver fibrosis staging F2-F3. Epidemiological data from the NASH Clinical Research Network suggest that approximately 37% of MASH patients with significant fibrosis are male, many in the 50- to 65-year age range [9]. BPH prevalence rises sharply with age, affecting roughly 50% of men aged 51 to 60 and 70% of men over 70 [10]. Saw palmetto is the most commonly used herbal supplement for BPH symptoms in the United States, with an estimated 2.5 million male users annually [3].

The practical consequence: a meaningful proportion of Rezdiffra-eligible patients are middle-aged or older men who may already be using saw palmetto before their MASH diagnosis is made and drug therapy initiated.

When Patients Do Not Disclose Supplements

A 2006 national survey published in the Archives of Internal Medicine found that 69% of adults using herbal supplements did not disclose their use to a physician [11]. Patients often do not consider over-the-counter supplements "real drugs" and omit them from medication lists. Prescribers starting a patient on Rezdiffra should ask specifically about saw palmetto, fish oil, and other lipid-active or liver-active botanicals.

Clinical Recommendations: What to Do If You Are Taking Both

Before Starting Rezdiffra

Tell your prescribing clinician about every supplement you take, including saw palmetto. Bring the bottle. The prescriber can review the dose, formulation type (lipophilic extract versus water-based), and frequency before making a recommendation.

If You Are Already Taking Both

Do not stop either agent unilaterally. Stopping resmetirom abruptly could allow MASH to progress. Stopping saw palmetto without a plan for BPH symptoms may worsen LUTS. Schedule a conversation with your prescriber to:

1. Confirm the saw palmetto dose and extract type.
2. Review baseline liver enzymes (ALT, AST) and LDL-C prior to any change.
3. Decide whether a 4- to 6-week washout of saw palmetto is appropriate before rechecking enzymes and lipids.
4. Consider whether a pharmaceutical BPH alternative (alpha-1 blocker such as tamsulosin, which does not inhibit CYP2C8) would manage symptoms with less pharmacokinetic uncertainty.

Monitoring Parameters

If both agents are continued, the HealthRX clinical team recommends:

• Liver enzymes (ALT, AST) at baseline and at 4 weeks after combining both agents.
• LDL-C and triglycerides at the standard Rezdiffra monitoring intervals (baseline, 12 weeks, then every 6 months per clinical judgment).
• Clinical bleeding assessment at each visit, especially if antiplatelet or anticoagulant agents are also present.
• Report any new right upper quadrant discomfort, jaundice, or unusual bruising promptly.

Dose Separation

Saw palmetto is typically taken once daily with food, as is Rezdiffra. Separating the doses by 4 to 6 hours may modestly reduce the peak inhibitory concentration of saw palmetto at CYP2C8 sites, but no clinical data confirm that dose separation meaningfully alters the interaction. This strategy is reasonable as a precaution but should not substitute for prescriber disclosure and monitoring.

Evidence Gaps and What Research Would Settle the Question

The interaction between saw palmetto and resmetirom has not been studied in a dedicated clinical pharmacokinetic trial. Three research gaps stand out:

Gap 1: No in vivo human pharmacokinetic study has measured the effect of standardized saw palmetto extract (320 mg/day) on the AUC and Cmax of a CYP2C8 substrate at therapeutically relevant concentrations.

Gap 2: Existing in vitro CYP2C8 inhibition data for saw palmetto use heterogeneous extract compositions, making IC50 values difficult to generalize to commercial products.

Gap 3: No prospective cohort or registry study has captured saw palmetto co-use rates among patients prescribed Rezdiffra in the post-approval setting.

Until those gaps are closed, the clinical posture is cautious co-monitoring rather than contraindication. The Endocrine Society's 2023 guidance on thyroid hormone analogues and drug interactions notes that "CYP2C8 substrates with a narrow therapeutic index warrant formal pharmacokinetic evaluation when co-administered with natural inhibitors of that enzyme" [12], a principle that applies directly here.

Alternatives to Saw Palmetto for BPH Symptoms in Rezdiffra Patients

If a prescriber and patient decide to discontinue saw palmetto because of interaction uncertainty, several pharmacological alternatives carry no CYP2C8 inhibitory activity:

• Tamsulosin (0.4 mg once daily): An alpha-1 adrenergic antagonist approved for BPH. Metabolized primarily by CYP3A4 and CYP2D6, not CYP2C8.
• Silodosin (8 mg once daily): Alpha-1A selective antagonist, metabolized by CYP3A4 and UGT2B7.
• Dutasteride (0.5 mg once daily): A pharmaceutical 5-AR inhibitor metabolized by CYP3A4, with no clinically meaningful CYP2C8 involvement.

Each of these options carries its own interaction and side-effect profile. The choice should be made by the treating clinician after reviewing the full medication list.

Summary of Interaction Classification

| Interaction Type | Mechanism | Evidence Level | Clinical Significance | |---|---|---|---| | CYP2C8 inhibition | Saw palmetto inhibits CYP2C8 in vitro, potentially raising resmetirom AUC | In vitro only (Tier 2) | Mild to moderate theoretical risk | | Antiplatelet effect | Saw palmetto reduces platelet aggregation | Case reports, in vitro | Low if no anticoagulant co-use; moderate if anticoagulant present | | Hepatotoxicity | Rare saw palmetto-associated cholestatic hepatitis in patients with pre-existing liver disease | Case reports | Low but monitor in MASH context | | 5-AR / hormonal | Saw palmetto inhibits 5-AR; no known interaction with THR-beta agonism | No evidence of interaction | Negligible |